Financials
Financial year 2025
Dr. Bastiaan Sol, Endocrinologie from Gent, company number BE0789462808, closed financial year 2025 with a result of € 222,948 after tax. For that financial year Dr. Bastiaan Sol, Endocrinologie recorded a gross margin of € 303,130 and equity of € 1,000. Compared with financial year 2024, the result moved from € 91,618 to € 222,948. Profitable, and profit is growing. The buffer shrank hard: equity is 99 % below last year. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on July 27, 2026.
€ 1,000
▼ 99% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 222,948
▲ 143% vs 2024
Profit after tax over the fiscal year.
€ 194,990
▲ € 148,074 vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 362,453 paid out
More than the year’s profit went to the shareholders; reserves fell.
People and assets in 2025
€ 20,895
▼ 32% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 21,115
▼ 32% vs 2024
€ 10,355 is repaid this year. At this pace the long-term loan is gone in ≈ 2 years.
€ 3,566
▲ 180% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 10,070
▼ 67% vs 2024
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 13,667 | € 150,598 | € 128,549 | € 303,130 | ▲ 136% |
| Profit after taxes | € 10,289 | € 107,599 | € 91,618 | € 222,948 | ▲ 143% |
| Equity | € 11,289 | € 118,888 | € 140,506 | € 1,000 | ▼ 99% |
| Total debts | € 60,242 | € 119,166 | € 138,606 | € 451,475 | ▲ 226% |
| Cash | € 20,717 | € 91,270 | € 46,916 | € 194,990 | ▲ € 148,074 |
| Retained profit | € 10,289 | € 117,888 | € 139,506 | € 0 | ▼ 100% |
| Dividend | € 0 | € 0 | € 70,000 | € 362,453 | ▲ € 292,453 |
| Bank debt | € 49,900 | € 40,671 | € 31,080 | € 21,115 | ▼ 32% |
| Balance sheet total | € 71,530 | € 238,054 | € 279,112 | € 452,475 | ▲ 62% |
Key figures of Dr. Bastiaan Sol, Endocrinologie, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Dr. Bastiaan Sol, Endocrinologie?
What happened at Dr. Bastiaan Sol, Endocrinologie in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 222,948 (▲ 143% vs 2024). Source: NBB ↗
- New establishment in Gent. KBO
- Bastiaan Sol became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 10,289 profit in 2022 to € 222,948 profit in 2025.
Paid € 129,924 in corporate taxes since 2022.
Best year ever: 2025, with € 222,948 profit.
Paid out € 432,453 in dividends to the owners in total.
Management
Behind Dr. Bastiaan Sol, Endocrinologie is Bastiaan Sol.
Directors
According to the 2025 annual accounts
Bastiaan Sol
Director
since 2022
Establishments
Establishment units
Physical locations of this company
Jan Verspeyenstraat 18
9000 Gent
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0789.462.808
- VAT number
- BE 0789.462.808
- Registered office
- Jan Verspeyenstraat 18, 9000 Gent
- Names & denominations
- Dr. Bastiaan Sol, Endocrinologie
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 8 August 2022
- Peppol
- Active · Active since 22 Aug 2025
- Activities · NACE
Activiteiten van medisch specialisten
Overige vormen van onderwijs